

AM26074PU-N**Monoclonal Antibody to HIV-1 Nef / HXB2 (31-35) - Aff - Purified**

| | |
|--------------------------|---|
| Alternate names: | HIV-I, HIV1, Human immunodeficiency virus type 1 |
| Quantity: | 0.1 mg |
| Concentration: | 1.0 mg/ml |
| Background: | HIV is a highly variable virus which mutates very readily. This means there are many different strains of HIV, even within the body of a single infected person. The strains of HIV1 can be classified into three groups: the "major" group M, the "outlier" group O and the "new" group N. These three groups may represent three separate introductions of simian immunodeficiency virus into humans. Group O appears to be restricted to West-Central Africa and group N, discovered in 1998 in Cameroon, is extremely rare. More than 90% of HIV1 infections belong to HIV1 group M. |
| Host / Isotype: | Mouse / IgG1 |
| Clone: | 3F2 (01-001) |
| Immunogen: | Recombinant Nef protein of HIV-1 HXB2 (purified from E. coli) |
| Format: | State: Liquid purified Ig fraction Purification: Affinity Chromatography on Protein G Buffer System: PBS, pH 7.4 Preservatives: 0.09% Sodium Azide |
| Applications: | Reacts in ELISA, Western blot, Immunoprecipitation and Immunohistochemistry on Frozen Sections with HIV-1 Nef of BRU, IIIB, LAV, HAN strains. Titer using rNef protein with subtype C a.a. consensus: ELISA: 1/5000. Western blot: 1/1000. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user. |
| Specificity: | This antibody detects HIV-1 Nef regulatory protein, mapped to amino acids 31-35 (-GAASR-, HIV-1 HXB2). Reacts with HIV-1 subtype C Nef of BRU, IIIB, LAV, HAN strains. |
| Storage: | Upon receipt, store (in aliquots) at -20 to -70 °C. Avoid repeated freezing and thawing. Shelf life: One year from despatch. |
| General Readings: | 1. Ovod V, Lagerstedt A, Ranki A, Gombert FO, Spohn R, Tähtinen M, et al. Immunological variation and immunohistochemical localization of HIV-1 Nef demonstrated with monoclonal antibodies. <i>AIDS</i> . 1992 Jan;6(1):25-34. PubMed PMID: 1371924. 2. Saito Y, Sharer LR, Epstein LG, Michaels J, Mintz M, Louder M, et al. Overexpression of nef as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues. <i>Neurology</i> . 1994 Mar;44(3 Pt 1):474-81. PubMed PMID: 8145918. 3. Ranki A, Nyberg M, Ovod V, Haltia M, Elovaara I, Raininko R, et al. Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with |

dementia. AIDS. 1995 Sep;9(9):1001-8. PubMed PMID: 8527071.

4. Collings A, Pitkänen J, Strengell M, Tähtinen M, Lagerstedt A, Hakkarainen K, et al. Humoral and cellular immune responses to HIV-1 nef in mice DNA-immunised with non-replicating or self-replicating expression vectors. Vaccine. 1999 Oct 14;18(5-6):460-7. PubMed PMID: 10519935.

5. Kjerrström A, Hinkula J, Engström G, Ovod V, Krohn K, Benthin R, et al. Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines. Virology. 2001 May 25;284(1):46-61. PubMed PMID: 11352667.

6. Blazevic V, Männik A, Malm M, Sikut R, Valtavaara M, Toots U, et al. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine. AIDS Res Hum Retroviruses. 2006 Jul;22(7):667-77. PubMed PMID: 16831091.

Pictures:

Western Blot testing of HIV-1 recombinant Nef protein using HIV-1 Nef antibody clone 3F2.

Line 1: Recombinant HIV-1 Nef (B subtype).

Line 2: Protein size marker.

